Sanofi anticipates low double-digit percentage growth in FY25 business EPS at constant exchange rates.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Should l Buy SNY?
- Sales Growth Projection: In 2025, sales are expected to increase by a high single-digit percentage at constant exchange rates (CER).
- Earnings Per Share (EPS) Outlook: Sanofi anticipates a strong rebound in business EPS, projecting growth at a low double-digit percentage at CER.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 46.140
Low
57.00
Averages
79.36
High
119.07
Current: 46.140
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oakmark Global Concentrated Strategy Outperforms MSCI World Index
- Strong Quarterly Performance: The Oakmark Global Concentrated Strategy achieved a return of 3.45% in Q4 2025, outperforming the MSCI World Index's 3.12% gain, demonstrating the effectiveness of its investment strategy and market adaptability.
- New Investment Position: In Q4 2025, the fund initiated a new position in Sanofi, indicating confidence in the company's future growth potential, which could yield long-term benefits for investors.
- Exit Strategy Adjustment: The fund exited its investments in Mercedes-Benz Group and Roche Holding during Q4 2025, reflecting its keen market awareness and optimization of the investment portfolio.
- Leadership Change: Sanofi replaced CEO Paul Hudson with Belén Garijo, and although the project rejuvenation remains unfinished, this change could bring new strategic direction and growth opportunities for the company.
See More
CDC Vaccine Advisory Committee Meeting Delayed to March
- Meeting Postponed: The CDC's Advisory Committee on Immunization Practices, originally scheduled for February 26, has been delayed to mid-March, with no finalized date, potentially impacting timely updates and implementation of vaccine policies.
- Legal Challenge: The postponement is linked to a lawsuit challenging recent changes made by HHS Secretary Robert F. Kennedy Jr. regarding committee member appointments, highlighting concerns over the transparency of CDC's decision-making, which may affect public trust in vaccinations.
- Medical Groups' Appeal: Several leading medical groups have urged a federal judge in Boston to bar the CDC from holding its next ACIP meeting, reflecting strong dissatisfaction with the committee member selection process, which could lead to increased resistance against CDC's vaccine policy formulation.
- Lack of CDC Response: The CDC and its parent agency, the U.S. Department of Health and Human Services, declined to comment on media inquiries, and this silence may further exacerbate public skepticism regarding its decision-making processes, impacting trust in the CDC.
See More
Impact Podcast Announces Star-Studded Guest Lineup
- Star-Studded Guest Lineup: The new season of the Impact Podcast features sustainability leaders from renowned brands like Mars, EY, and Prologis, showcasing their daily contributions to making the world a better place, which is expected to draw significant audience interest.
- Innovative Format: The podcast's newly designed user-friendly homepage enhances user experience, allowing listeners easier access to content and further amplifying the show's impact across digital platforms.
- Diverse Topics: Upcoming episodes will include a multi-part conversation with cancer survivor Dr. Dawn Mussallem, sharing her extraordinary journey, aimed at inspiring listeners to reflect on health and the meaning of life.
- Wide Listening Channels: The podcast is available on multiple platforms, including Spotify, Apple Podcasts, and YouTube Music, ensuring a broader audience can access these important sustainability stories.
See More
FDA Grants Breakthrough Therapy Designation for Rybrevant
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy Designation for Rybrevant (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma, applicable to patients with recurrent or metastatic disease after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, indicating strong recognition and market potential for the new therapy.
- Contract Extension: The collaboration agreement signed by Johnson & Johnson in January 2025 has been extended to mid-2026 under the same economic terms, including a fixed monthly management fee, driven by strong engagement and satisfaction metrics, reflecting ongoing confidence in the program's performance.
- Market Model Development: Trellus Health CEO Marla Dubinsky stated that the company is establishing a scalable go-to-market model for pharmaceuticals, focusing on disciplined execution, recurring revenue growth, and expansion in immunology and inflammation, showcasing a positive outlook for future developments.
- Financial Outlook: Trellus Health expects fiscal 2025 revenue to be approximately $545,000 and has reduced its monthly cash burn to around $400,000, demonstrating improved financial management and confidence in future growth prospects.
See More
Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment
- Clinical Trial Results: Ocular Therapeutix reported that 74.1% of patients maintained vision at Week 36 in the SOL-1 Phase 3 trial for Axpaxli, compared to 65.9% in the Eylea group, with a risk difference of 17.5% (p=0.0006); however, the durability advantage fell short of expectations, potentially impacting its commercial outlook.
- Next Steps: The company intends to submit a New Drug Application (NDA) based on the SOL-1 data, and if approved, Axpaxli could become the first tyrosine kinase inhibitor (TKI) commercialized for wet AMD, potentially being the only therapy with a superiority label, which holds significant strategic implications.
- Market Reaction: Ocular Therapeutix shares fell 26.46% in premarket trading, currently priced at $6.62, reflecting market disappointment over the Axpaxli data, despite a 23.33% increase over the past 12 months, indicating a generally positive long-term trend.
- Analyst Ratings: The stock maintains a Buy rating with an average price target of $21.00, with Chardan Capital and Needham keeping their targets unchanged, while HC Wainwright raised its target to $21.00, reflecting analysts' optimistic outlook for the future.
See More
Sanofi Appoints New Head of Specialty Care
- Leadership Change: Sanofi has announced the appointment of Manuela Buxo as the new Head of Specialty Care, effective March 1, 2026, succeeding Brian Foard, who is leaving the company on February 28, 2026, after successfully launching key medicines like Dupixent globally.
- Experienced Successor: Manuela, currently leading the Global Immunology Alliance Franchise, brings over 20 years of international healthcare experience, particularly in Specialty Care in Europe, and her leadership is expected to further drive the dynamic development of Sanofi's Specialty Care business.
- Commitment to Business Continuity: Sanofi reaffirms its commitment to Specialty Care priorities during this transition, ensuring continuity of execution and maintaining competitive advantages in the market despite leadership changes.
- Positive Executive Remarks: Interim CEO Olivier Charmeil expressed gratitude for Brian's contributions and confidence in Manuela's extensive experience and long-standing commitment to Sanofi, believing she will ensure strong continuity and rapid progress for the business.
See More
Oakmark Global Concentrated Strategy Outperforms MSCI World Index
- Strong Quarterly Performance: The Oakmark Global Concentrated Strategy achieved a return of 3.45% in Q4 2025, outperforming the MSCI World Index's 3.12% gain, demonstrating the effectiveness of its investment strategy and market adaptability.
- New Investment Position: In Q4 2025, the fund initiated a new position in Sanofi, indicating confidence in the company's future growth potential, which could yield long-term benefits for investors.
- Exit Strategy Adjustment: The fund exited its investments in Mercedes-Benz Group and Roche Holding during Q4 2025, reflecting its keen market awareness and optimization of the investment portfolio.
- Leadership Change: Sanofi replaced CEO Paul Hudson with Belén Garijo, and although the project rejuvenation remains unfinished, this change could bring new strategic direction and growth opportunities for the company.
See More
CDC Vaccine Advisory Committee Meeting Delayed to March
- Meeting Postponed: The CDC's Advisory Committee on Immunization Practices, originally scheduled for February 26, has been delayed to mid-March, with no finalized date, potentially impacting timely updates and implementation of vaccine policies.
- Legal Challenge: The postponement is linked to a lawsuit challenging recent changes made by HHS Secretary Robert F. Kennedy Jr. regarding committee member appointments, highlighting concerns over the transparency of CDC's decision-making, which may affect public trust in vaccinations.
- Medical Groups' Appeal: Several leading medical groups have urged a federal judge in Boston to bar the CDC from holding its next ACIP meeting, reflecting strong dissatisfaction with the committee member selection process, which could lead to increased resistance against CDC's vaccine policy formulation.
- Lack of CDC Response: The CDC and its parent agency, the U.S. Department of Health and Human Services, declined to comment on media inquiries, and this silence may further exacerbate public skepticism regarding its decision-making processes, impacting trust in the CDC.
See More
Impact Podcast Announces Star-Studded Guest Lineup
- Star-Studded Guest Lineup: The new season of the Impact Podcast features sustainability leaders from renowned brands like Mars, EY, and Prologis, showcasing their daily contributions to making the world a better place, which is expected to draw significant audience interest.
- Innovative Format: The podcast's newly designed user-friendly homepage enhances user experience, allowing listeners easier access to content and further amplifying the show's impact across digital platforms.
- Diverse Topics: Upcoming episodes will include a multi-part conversation with cancer survivor Dr. Dawn Mussallem, sharing her extraordinary journey, aimed at inspiring listeners to reflect on health and the meaning of life.
- Wide Listening Channels: The podcast is available on multiple platforms, including Spotify, Apple Podcasts, and YouTube Music, ensuring a broader audience can access these important sustainability stories.
See More
FDA Grants Breakthrough Therapy Designation for Rybrevant
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy Designation for Rybrevant (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma, applicable to patients with recurrent or metastatic disease after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, indicating strong recognition and market potential for the new therapy.
- Contract Extension: The collaboration agreement signed by Johnson & Johnson in January 2025 has been extended to mid-2026 under the same economic terms, including a fixed monthly management fee, driven by strong engagement and satisfaction metrics, reflecting ongoing confidence in the program's performance.
- Market Model Development: Trellus Health CEO Marla Dubinsky stated that the company is establishing a scalable go-to-market model for pharmaceuticals, focusing on disciplined execution, recurring revenue growth, and expansion in immunology and inflammation, showcasing a positive outlook for future developments.
- Financial Outlook: Trellus Health expects fiscal 2025 revenue to be approximately $545,000 and has reduced its monthly cash burn to around $400,000, demonstrating improved financial management and confidence in future growth prospects.
See More
Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment
- Clinical Trial Results: Ocular Therapeutix reported that 74.1% of patients maintained vision at Week 36 in the SOL-1 Phase 3 trial for Axpaxli, compared to 65.9% in the Eylea group, with a risk difference of 17.5% (p=0.0006); however, the durability advantage fell short of expectations, potentially impacting its commercial outlook.
- Next Steps: The company intends to submit a New Drug Application (NDA) based on the SOL-1 data, and if approved, Axpaxli could become the first tyrosine kinase inhibitor (TKI) commercialized for wet AMD, potentially being the only therapy with a superiority label, which holds significant strategic implications.
- Market Reaction: Ocular Therapeutix shares fell 26.46% in premarket trading, currently priced at $6.62, reflecting market disappointment over the Axpaxli data, despite a 23.33% increase over the past 12 months, indicating a generally positive long-term trend.
- Analyst Ratings: The stock maintains a Buy rating with an average price target of $21.00, with Chardan Capital and Needham keeping their targets unchanged, while HC Wainwright raised its target to $21.00, reflecting analysts' optimistic outlook for the future.
See More
Sanofi Appoints New Head of Specialty Care
- Leadership Change: Sanofi has announced the appointment of Manuela Buxo as the new Head of Specialty Care, effective March 1, 2026, succeeding Brian Foard, who is leaving the company on February 28, 2026, after successfully launching key medicines like Dupixent globally.
- Experienced Successor: Manuela, currently leading the Global Immunology Alliance Franchise, brings over 20 years of international healthcare experience, particularly in Specialty Care in Europe, and her leadership is expected to further drive the dynamic development of Sanofi's Specialty Care business.
- Commitment to Business Continuity: Sanofi reaffirms its commitment to Specialty Care priorities during this transition, ensuring continuity of execution and maintaining competitive advantages in the market despite leadership changes.
- Positive Executive Remarks: Interim CEO Olivier Charmeil expressed gratitude for Brian's contributions and confidence in Manuela's extensive experience and long-standing commitment to Sanofi, believing she will ensure strong continuity and rapid progress for the business.
See More
